OptiBiotix Health PLC Proposed Director appointment (6261N)
02 February 2021 - 06:00PM
UK Regulatory
TIDMOPTI
RNS Number : 6261N
OptiBiotix Health PLC
02 February 2021
Opti B i otix Health plc
( "Opti Bi o t ix" or the "Company")
Proposed Director appointment
Directorate change
OptiBi otix Health p lc (AI M : OPTI), a life sciences busi ness
d e vel o ping co m p o u n ds to tack le o besit y, high choleste
r ol, diabetes and skincare, a nn o unces that it intends to
appoint Stephen Hammond MP, as a Non- Executive Director of the
Company, subject to the completion of regulatory due diligence
being carried out by the Company's Nomad.
Stephen has been a Member of Parliament since 2005, fulfilling
roles as Parliamentary Under Secretary of State for Transport from
2012 to 2014 and more recently Minister of State for the Department
of Health and Social Care from 2018 to 2019.
Prior to his role in politics, Stephen had a successful career
in finance at a leading fund management house and at a number of
major European investment banks. He was a Director of the Equities
division of Dresdner Kleinwort Benson from 1994 to 1998, a private
bank providing financial services to high net worth individuals and
corporate clients in the UK. After this he joined Commerzbank
Securities, a leading international commercial bank described as
'Germany's Leading Brokerage Firm' of the past 10 years (
https://tinyurl.com/y5re88mg ), with branches and offices in nearly
50 countries. He was with Commerzbank Securities from 1998 until
2003. During this time, Stephen was promoted to Director in Pan
European Research, with the responsibility for 70 professionals
based in London and across Europe, before becoming an MP in
2005.
A further announcement will be made in due course.
Neil Davidson, Chairman of OptiBiotix commented: "Stephen's
appointment reflects the continued evolution and ambition of the
Board as the Company moves into the next phase of its development
in becoming a profitable international business with global brands.
Stephen's international understanding of healthcare, finance and
experience of working in senior positions within finance and
government complements the current Board's wealth of
experience.
"The Company anticipate that there will be further additions and
changes to the Board and management teams as it continues to grow
sales, expand into international markets and commercialises its
next generation products."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
The Directors of the Company accept responsibility for the
content of this announcement.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Neil Davidson, Chairman Contact via Walbrook
below
Stephen O'Hara, Chief Executive
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
Cenkos Securities plc (Broker) Tel: 020 7397 8900
Callum Davidson / Neil McDonald
Michael Johnson / Russell Kerr (Sales)
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D programme working with
leading academics in the development of microbial strains,
compounds, and formulations which are used as active ingredients
and supplements. More than twenty international food and healthcare
supplement companies have signed agreements with OptiBiotix to
incorporate their human microbiome modulators into a wide range of
food products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed
to be, forward looking statements. Forward looking statements are
identi ed by their use of terms and phrases such as "believe",
"could", "should" "envisage", "estimate", "intend", "may", "plan",
"potentially", "expect", "will" or the negative of those,
variations or comparable expressions, including references to
assumptions. These forward looking statements are not based on
historical facts but rather on the Directors' current expectations
and assumptions regarding OptiBiotix's future growth, results of
operations, performance, future capital and other expenditures
(including the amount, nature and sources of funding thereof),
competitive advantages, business prospects and opportunities. Such
forward looking statements re ect the Directors' current beliefs
and assumptions and are based on information currently available to
the Directors.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOADZGGZNMKGMZM
(END) Dow Jones Newswires
February 02, 2021 02:00 ET (07:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Feb 2024 to Mar 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Mar 2023 to Mar 2024